Research Topics
| Joseph M BlondeauSummaryAffiliation: University of Saskatchewan Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?Glenn S Tillotson
Replidyne Inc, 472 Wheelers Farms Rd, Milford, CT 06460, USA
Expert Rev Anti Infect Ther 5:53-9. 2007..This inexorable increase is occurring in the face of a dearth of new antibiotics for community use and even fewer for treating resistant nosocomial gram-negative species. The possible strategies and consequences are discussed...
Canadian Multicenter Susceptibility Study, with a focus on cephalosporins, from 15 Canadian medical centers. The Canadian Multicenter Study GroupJ M Blondeau
Division of Clinical Microbiology, Saskatoon and District Health and St Paul s Hospital Grey Nuns, and the University of Saskatchewan, Canada
Antimicrob Agents Chemother 41:2773-5. 1997..Cefoperazone activity against Pseudomonas aeruginosa was 87%, compared to 92% for ticarcillin-clavulanate. All agents had 97% or greater activity against Staphylococcus aureus...- Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniaeJ M Blondeau
Departments of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon District Health, Saskatchewan, Canada
Antimicrob Agents Chemother 45:433-8. 2001.... - Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infectionsJ M Blondeau
Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns and Department of Pathology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Expert Opin Investig Drugs 10:213-37. 2001.... - Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety featuresJ M Blondeau
Department of Clinical Microbiology, Royal University Hospital and the University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan S7N 0W8, Canada
Expert Opin Pharmacother 2:317-35. 2001..For example, some new compounds require once daily dosing, have minimal side effects, are active against resistant pathogens and, for some, have a lower propensity for selecting for antimicrobial resistance during patient therapy... - Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agentsJ M Blondeau
Department of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon District Health, The University of Saskatchewan, Saskatchewan, S7N 0W8, Saskatoon, Canada
Int J Antimicrob Agents 17:457-64. 2001..The prevalence of beta-lactamase positive H. influenzae may have decreased from levels reported in previous studies... - Extended-spectrum beta-lactamasesJ M Blondeau
Department of Clinical Microbiology, Royal University and Saskatoon City Hospitals, Saskatchewan, Canada
Semin Respir Infect 16:169-76. 2001..Additionally, some laboratories may have difficulty detecting ESBL-producing organisms. These and other issues are discussed in this article... - The role of fluoroquinolones in skin and skin structure infectionsJoseph M Blondeau
Clinical Microbiology, Saskatoon and District Health Royal University and Saskatoon City Hospitals and St Paul s Hospital, Saskatoon, Saskatchewan, Canada
Am J Clin Dermatol 3:37-46. 2002..At present, quinolones are, in general, equivalent to beta-lactam agents in the treatment of skin and soft tissue infection... - The macrolidesJoseph M Blondeau
Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Saskatoon, Saskatchewan, Canada
Expert Opin Investig Drugs 11:189-215. 2002..While resistance is problematic, it does not always result in clinical failure. The macrolides are a valuable class of antimicrobial agent and play an important role in the management of infectious diseases... - The evolution and role of macrolides in infectious diseasesJoseph M Blondeau
Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Royal University Hospital, University of Saskatchewan, Canada
Expert Opin Pharmacother 3:1131-51. 2002..The multitude of studies substantiating clinical as well as bacteriological success with these two agents indicates that, when used appropriately, they will stand the test of time and continue to be useful antimicrobial agents... - Quinupristin/dalfopristinJoseph M Blondeau
Department of Clinical Microbiology, Saskatoon and District Health and the University of Saskatchewan, Canada
Expert Opin Pharmacother 3:1341-64. 2002.... - In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinoloneJ M Blondeau
Departments of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Saskatchewan, Saskatoon, Canada S7N 0W8
Int J Antimicrob Agents 22:147-54. 2003.... - A review of antimicrobial resistance in CanadaJ M Blondeau
Department of Clinical Microbiology, St Paul s Hospital Grey Nuns, Saskatoon, SK, Canada
Can J Microbiol 46:867-77. 2000..In addition, future concerns and programs for ongoing surveillance are discussed... - Gatifloxacin: a new fluoroquinoloneJ M Blondeau
Department of Clinical Microbiology, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8, Canada
Expert Opin Investig Drugs 9:1877-95. 2000..Clinical trial data supports the use of gatifloxacin for treatment of patients with respiratory tract, urinary tract, skin and soft tissue infections. The side effect profile for gatifloxacin is similar to that with other agents... - A review of clinical trials with fluoroquinolones with an emphasis on new agentsJ M Blondeau
Department of Clinical Microbiology, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan S7N 0W8, Canada
Expert Opin Investig Drugs 9:383-413. 2000..These attributes, coupled with their expanded spectrum suggest that the newer fluoroquinolones are so far the most ideal agents for the empirical treatment of many common infections... - In vitro evaluation of G1: a novel antimicrobial compoundJ M Blondeau
Department of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon and District Health, Saskatchewan, Canada
Int J Antimicrob Agents 11:163-6. 1999..G1 appears to be a novel antimicrobial agent with broad spectrum activity against bacterial and fungal pathogens. Defining the activity of this compound against multi-resistant bacteria is a priority... - In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study GroupJ M Blondeau
Division of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns and the University of Saskatchewan, Saskatoon, Canada
J Antimicrob Chemother 43:3-23. 1999..Seventeen agents had activity against > or = 95% of Staphylococcus aureus strains. Susceptibility of Pseudomonas aeruginosa isolates ranged from 2% to 91%... - Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study GroupJ M Blondeau
Saskatoon District Health and St Paul s Hospital Grey Nuns and the Department of Pathology, University of Saskatchewan, Saskatoon, Canada
J Antimicrob Chemother 43:25-30. 1999..75 and > or = 256 mg/L, respectively). This study indicates the increasing incidence, in Canada, of beta-lactamase resistance in H. influenzae and M. catarrhalis and penicillin resistance in S. pneumoniae... - A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'J M Blondeau
Department of Clinical Microbiology, Saskatoon District Health, St Paul s Hospital Grey Nuns, Royal University Hospital and the University of Saskatchewan, Canada
J Antimicrob Chemother 43:1-11. 1999.... - In vitro activity of several antimicrobial agents against 1003 isolates of Streptococcus pyogenes collected from Western CanadaJ M Blondeau
St Paul s Hospital and Saskatoon District Health and the Department of Microbiology, University of Saskatchewan, Canada
Int J Antimicrob Agents 12:67-70. 1999..4%, clarithromycin 98.5%, clindamycin 99.9%, erythromycin 96.5% and penicillin 100%. These results indicate that antimicrobial resistance is not yet a problem of S. pyogenes in Canada... - Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infectionsJ M Blondeau
Saskatoon and District Health and St Paul s Hospital Grey Nuns and the University of Saskatchewan, Canada
Int J Antimicrob Agents 12:145-50. 1999..In this paper the formula is applied to community- and hospital-acquired urinary tract infections... - In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. Canadian Afermenter Study GroupJ M Blondeau
Department of Clinical Microbiology, St Paul s Hospital Grey Nuns, Saskatchewan, Canada
J Antimicrob Chemother 44:545-8. 1999..4 and 15.6%, respectively. This in-vitro study showed that cefepime may be a useful additional agent in the treatment of infections caused by P. aeruginosa and Acinetobacter spp., but not when S. maltophilia is considered pathogenic... - Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organismsJ M Blondeau
Departments of Clinical Microbiology and Pathology, Saskatoon District Health, St Paul s Hospital Grey Nuns, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Canada
Int J Antimicrob Agents 14:45-50. 2000..Our data indicate that the advanced fluoroquinolones will be important compounds for treating infections caused by Gram-positive and Gram-negative pathogens... - In vitro activity of 19 antimicrobial agents against 3513 nosocomial pathogens collected from 48 Canadian medical centres. The Canadian Antimicrobial Study GroupJ M Blondeau
Division of Clinical Microbiology, Saskatoon and District Health, Royal University Hospital, University of Sasktchewan, Canada
Int J Antimicrob Agents 15:213-9. 2000..The control of antimicrobial resistance can help maintain antibiotic usage and costs associated with the use of ever more potent drugs and the treatment of increasingly resistant infections... - Antimicrobial susceptibility patterns of respiratory pathogens--a global perspectiveJ M Blondeau
Saskatoon District Health and St Paul s Hospital Grey Nuns and the University of Saskatchewan, Canada
Semin Respir Infect 15:195-207. 2000..Also, mechanisms of resistance and factors associated with the emergence, dissemination, and colonization of resistant organisms are discussed... 
Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strainsChristine K Hesje
Department of Clinical Microbiology, University of Saskatchewan, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada
J Ocul Pharmacol Ther 25:329-34. 2009....- Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzaePeter Hedlin
Department of Clinical Microbiology, Royal University Hospital and Saskatoon Health Region, Saskatoon, Saskatchewan, Canada
Eye Contact Lens 33:161-4. 2007..e., ciprofloxacin and ofloxacin) and fourth-generation (i.e., gatifloxacin and moxifloxacin) fluoroquinolone antibiotics against clinical ocular isolates of H. influenzae... - Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosaGlen T Hansen
Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Int J Antimicrob Agents 27:120-4. 2006..For individual isolates, the MPC correlated poorly with the minimum inhibitory concentration (r(2) = 0.41 and 0.39 for ciprofloxacin and levofloxacin, respectively)... - Role of gemifloxacin in the management of community-acquired lower respiratory tract infectionsJoseph M Blondeau
Department of Clinical Microbiology, Royal University Hospital and the Saskatoon Health Region, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
Int J Antimicrob Agents 31:299-306. 2008..Moreover, it is generally well tolerated and is as safe as many frequently empirically prescribed antimicrobials. In addition, studies have shown gemifloxacin to be a cost-effective agent for some lower RTIs... - Fluoroquinolones: mechanism of action, classification, and development of resistanceJoseph M Blondeau
Department of Clinical Microbiology, Royal University Hospital, Saskatoon, Saskatchewan, Canada
Surv Ophthalmol 49:S73-8. 2004..This article also highlights the mechanism of resistance among common ocular pathogens and discusses the potential need for newer fluoroquinolones in ophthalmology... - Gemifloxacin: a new fluoroquinoloneJoseph M Blondeau
Department of Microbiology, Royal University Hospital, Saskatoon, Saschatchewan, Canada
Expert Opin Pharmacother 5:1117-52. 2004..Gemifloxacin is a welcomed addition to currently available agents for the treatment of community-acquired lower respiratory tract infections. Other potential indications appear to be within the spectrum of this compound... - New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approachJoseph M Blondeau
Department of Clinical Microbiology, Royal University Hospital, Canada S7N 0W8
Vet Dermatol 20:383-96. 2009..In today's environment, resistance prevention should be a goal of antimicrobial therapy... - [Gemifloxacin for the treatment of uncomplicated urinary infections (acute cystitis)]Joseph M Blondeau
Departamento de Microbiologia Clinica, Hospital de la Royal Univesity y Saskatoon Health Region, Saskatchewan, Canada
Ginecol Obstet Mex 77:573-82. 2009..Gemifloxacin showed to be safe and well tolerated. A dose a day is a safe and useful alternative amongst current empirical options to treat patients with uncomplicated urinary infections... - Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment optionJoseph M Blondeau
Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan S7N 0W8, Canada
Drugs 64:611-28. 2004.... - Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniaeKelli Metzler
Department of Pathology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
J Antimicrob Chemother 68:631-5. 2013.... - Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniaeGlen T Hansen
Antimicrob Agents Chemother 47:440-1. 2003 - Optimal antimicrobial therapy: the balance of potency and exposureGlenn S Tillotson
Expert Opin Investig Drugs 15:335-7. 2006.... - Low correlation between MIC and mutant prevention concentrationKarl Drlica
Antimicrob Agents Chemother 50:403-4. 2006 - Antimicrobial development and the risk-benefit assessment: recent adverse events and their implicationsGlenn S Tillotson
Expert Rev Anti Infect Ther 4:515-7. 2006